CWBR CohBar is a clinical stage biotechnology company which develops mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. CWBR closed few months ago a $15.0 Million Offering of Common Stock and Warrants at $0.72, so this is a safe upside in my opinion if you want to enter now. Cantor Fitzgerald brokerage has a $2.5...
CWBR closed 2 months ago a $15.0 Million Public Offering of Common Stock and Warrants at $0.72, so this is a safe upside in my opinion if you want to enter now. On the other hand, Cantor Fitzgerald brokerage has a $2.5 price target for it. 52 Week Range 0.34 - 2.27 Just bounced from its lowest support.
I think antiaging stocks will be the new FAANGS in 5 to 10 years. Immortality here, on earth, is the next frontier for the medicine. CohBar is developing mitochondria-based therapeutics for the treatment of chronic and age-related diseases. On 11/12/2021 Cantor Fitzgerald brokerage Initiated Coverage on CWBR with an Overweight rating and a price target of...
CWBR CohBar is developing mitochondria based therapeutics for the treatment of age-related diseases. So it`s an anti-aging listed companies. They released positive topline results from an early stage study into CB4211, a drug under development for the treatment of nonalcoholic steatohepatitis, but after a 70% increase, the stock went even lower than before the...